What is Attagene?
Based in Research Triangle Park, North Carolina, Attagene has been a pioneer in drug development and toxicity testing since its inception in 2001. The company is best known for its proprietary FACTORIAL technology, a sophisticated platform designed for the simultaneous assessment of multiple endpoints in live cells. This innovation provides researchers with highly reproducible activity profiles, which are essential for the rigorous evaluation of drug candidates. By maintaining an extensive database of molecular signatures, Attagene enables its partners in academia, regulatory agencies, and the biopharmaceutical industry to identify novel candidates with high on-target efficacy and minimal off-target toxicity, effectively streamlining the drug discovery pipeline.
How much funding has Attagene raised?
Attagene has raised a total of $111K across 1 funding round:
Debt
$111K
Debt (2021): $111K with participation from PPP
Key Investors in Attagene
PPP
Public-Private Partnership
What's next for Attagene?
With the successful completion of this late-stage financing, Attagene is poised to scale its FACTORIAL platform to meet the increasing demand for high-throughput, cost-efficient cell response profiling. The strategic deployment of this capital will likely focus on enhancing the company's database capabilities and expanding its footprint in the competitive drug discovery market. As the industry shifts toward more precise, data-driven development methodologies, Attagene's ability to provide actionable insights into cellular responses will be a critical differentiator. Future growth trajectories will likely involve deeper integration with large-scale pharmaceutical R&D workflows, further cementing the company's status as a vital infrastructure provider in the life sciences sector.
See full Attagene company page
